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Background
CANDLE is a novel autoinflammatory syndrome present-
ing early in infancy with attacks of fever, panniculitis,
arthritis, myositis, lipodystrophy, cytopenias, dyslipidemia
and growth retardation. CANDLE is caused by mutations
in a number of proteasome-associated genes including
PSMA3, PSMB4, PSMB8 and PSMB9. Elevated serum
IP-10 (CXCL10) levels and gene expression studies show
a prominent “interferon (IFN) signature”. These findings
and the successful in vitro blocking studies with Janus
kinases (JAKs) inhibitors, raised the question whether
IFN could be a therapeutic target in CANDLE.
Objectives
The objective of this compassionate use study
(NCT01724580) is to determine whether the treatment
with baricitinib (JAK1/JAK2 inhibitor) results in the
reduction of the mean Autoinflammatory Diary Score
(ADS) to below 0.5 (ranges 0-4) and to determine
whether treatment with baricitinib allows reduction of
steroid doses by at least 50% in patients receiving ster-
oids at baseline.
Methods
Patients with CANDLE are eligible to participate in the
study. Statistical analyses were performed using a paired
t-test to compare baseline to last clinic visit data. Bariciti-
nib dosing is based on a defined dose-escalation scheme.
Patients who are unresponsive to treatment may have
their dose escalated. Demographics, vital signs, safety
laboratories, ADS, adverse events (AEs) and prednisone
doses are captured at each visit.
Results
To date, 12 CANDLE patients have been enrolled. One
patient discontinued from the study due to lack of effi-
cacy and development of debilitating avascular necrosis.
All patients have been followed for at least 6 months
(mean 1.7 years). The mean ADS decreased significantly
(1.3 (SD± 0.8) at baseline, 0.3 (SD± 0.3) at the time of
their last visit, p <0.005). The mean total prednisone
dose of 14 mg/day (SD± 8.5) decreased by 73% to
3.8 mg/day (SD± 3.6). Four patients discontinued pre-
dnisone completely. Myositis has improved in 5 out of
6 patients and signs of bone marrow immunosuppres-
sion have improved in all but 1 patient (subject#1008),
with increases of platelets, absolute lymphocyte counts
(p <0.05) and hemoglobin. Seventeen serious adverse
events (SAEs) were reported in 4 patients (presumed
Pneumocystis jiroveci pneumonia, avascular necrosis,
urinary tract, port cath-related, rotavirus, and C. difficile
infections). The most common adverse events were
upper respiratory infections, two patients have devel-
oped anemia. One patient has been treated successfully
with IV iron.
The mean dose of baricitinib at last patient visit was
8.5 mg/day (SD± 2.1).
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Conclusion
Preliminary data in 11 CANDLE patients treated with bar-
icitinib are encouraging and suggest that targeting IFN sig-
naling with a JAK1/JAK2 inhibitor may be a successful
therapeutic strategy for CANDLE patients, and possibly
other IFN mediated autoinflammatory disorders.
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